A Study of Pitolisant in Participants With Prader-Willi Syndrome
Status:
ENROLLING_BY_INVITATION
Trial end date:
2030-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess safety of pitolisant in eligible participants with Prader-Willi syndrome (PWS) who completed the End of Treatment (EOT) visit in a parent study (HBS-101-CL-002 \[Open Label Extension (OLE)\], HBS- 101-CL-004, or HBS-101-CL-312 OLE).